Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. www.goldcopd.org.
Deesomchok A, Webb KA, Forkert L, Lam YM, Ofir D, Jensen D et al. Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. COPD, 2010, 7(6): 428-437.
Santus P, Radovanovic D, Henchi S, Di Marco F, Centanni S, D’Angelo E et al. Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients. Respir. Physiol. Neurobiol., 2014, 15: 36-45.
Chapman KR, Beeh KM, Beier J, Bateman ED, D’Urzo A , Nutbrown R et al. A blinded evaluation of the efficacy and safety of glycopyrroni-um, a once-daily longacting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm. Med., 2014. 14: 4.
Трофименко И.Н., Черняк Б.А. Бронхиальная гиперреактивность как фенотипическая характеристика хронической обструктивной болезни легких. Пульмонология, 2011, 4: 49-53.
Garcia-Aymerich J, Agustí A, Barberà JA, Belda J, Farrero E, Ferrer A et al. Phenotypic heterogeneity of chronic obstructive pulmonary disease. Arch. Bronconeumol., 2009, 45(3): 133-142.
Zanini A, Cherubino F, Zampogna E, Croce S, Pignatti P, Spanevello A. Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis., 2015, 10: 1155-1161.
Трофименко И.Н., Черняк Б.А. Предикторы тяжелой одышки у больных хронической обструктивной болезнью легких средней степени тяжести. Пульмонология, 2014, 2: 55-59.
Трофименко И.Н., Черняк Б.А. Динамика клинико-функционального статуса и показателей воспаления у больных хронической обструктивной болезнью легких в процессе терапии тиотропием. Мед. совет, 2015, 16: 8-13.
Ho spers JJ, Postma DS, Rijcken B, Weiss ST, Schouten JP. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet, 2000, 356: 1313-1317.
Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am. J. Med., 2004, 117: 24-32.
Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc., 2005, 2: 297-304.
Abad Santos F, Novalbos J, Gallego Sandín S, Gálvez Múgica MA. Regulation of bronchial tone in chronic obstructive pulmonary disease (COPD): role of muscarinic receptors. An. Med. Interna., 2003, 20(4): 201-205.
Buels KS, Fryer AD. Muscarinic receptor antagonists: effects on pulmonary function. Handb. Exp. Pharmacol., 2012, 208: 317-341.
Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the patho-physiology of asthma and COPD. Respir. Res., 2006, 7: 73.
O’Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am. J. Respir. Crit. Care Med., 1996, 154: 876-880.
Blais CM, Davis BE, Cockcroft DW. Duration of bronchoprotection of the long-acting mus-carinic antagonists tiotropium & glycopyrroni-um against methacholine-induced bronchoconstriction in mild asthmatics. Respir Med., 2016., 118: 96-101.
Klein G, Kӧhler D, Bauer CP. Standartization of inhalation challenges for measuring the unspecific bronchial inhalation challenge by reservuar-method. Pneumologie, 1991, 45: 60-64.
Стандартизация легочных функциональных тестов. Пер. с англ. под ред. А.Г. Чучалина. Пульмонология (приложение), 1993: 60-69.
Gulsvik A, Refvem OK. Ascoring system on respiratory symptoms. Eur. Respir. J., 1988, 1: 428-432.
Marin JM, Beeh KM, Clemens A, Castellani W, Schaper L, Saralaya D et al. Early bronchodilator action of glycopyrronium versus tiotropi-um in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING). Int. J. Chron. Obstruct. Pulmon. Dis., 2016, 11: 1425-1434.
Arievich H, Overend T, Renard D, Gibbs M, Alagappan V, Looby M et al. A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulm. Med. , 2012, 12: 74.
Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Fawcett L, Renard E, et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J. Pharmacol. Exp. Ther., 2012, 343: 520-8.
Miravitlles M, Beeh K-M, Altman P. Glycopyrronium for chronic obstructive pulmonary disease: evidence and rationale for use from the GLOW trials. Clin. Invest. (Lond.), 2014, 4(12): 1095–1111.
D’Urzo A, Ferguson GT, van Noord JA et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir. Res., 2011, 7(12) 156: 2-13.
Kerwin E, Hébert J, Gallagher N et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur. Respir. J., 2012, 40: 1106-1114.